SLNSilence Therapeutics plc

Nasdaq silence-therapeutics.com


$ 19.03 $ 0.00 (0 %)    

Friday, 28-Jun-2024 15:59:39 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 19
$ 19.21
$ 0.00 x 0
$ 0.00 x 0
$ 19.00 - $ 19.37
$ 4.84 - $ 27.72
290,651
na
2.26B
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-silence-therapeutics-raises-price-target-to-49

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target...

 chardan-capital-maintains-buy-on-silence-therapeutics-raises-price-target-to-55

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and raises the price target from $...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 silence-therapeutics-reports-results-from-ongoing-sanreco-phase-1-repeat-dose-study-of-divesiran-says-data-support-advancing-divesiran-into-phase-2

Of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline.  To date, d...

 silence-therapeutics-to-receive-2m-research-milestone-payment-from-hansoh-pharma-following-the-achievement-of-a-second-undisclosed-milestone-related-to-the-first-target-under-the-collaboration

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 chardan-capital-maintains-buy-on-silence-therapeutics-maintains-42-price-target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $42 price target.

 morgan-stanley-maintains-overweight-on-silence-therapeutics-maintains-45-price-target

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and maintains $45 price tar...

 silence-therapeutics-announces-jama-publication-of-additional-apollo-phase-1-data-for-zerlasiran-in-subjects-with-elevated-lipoproteina

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 these-analysts-boost-their-forecasts-on-silence-therapeutics-after-full-year-2023-results

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.

 morgan-stanley-maintains-overweight-on-silence-therapeutics-raises-price-target-to-45

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target...